Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer

Cancer Treat Rep. 1976 Jan;60(1):115-7.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use*
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use*
  • Drug Therapy, Combination
  • Fluorouracil / adverse effects
  • Fluorouracil / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Prostatic Neoplasms / drug therapy*

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil